Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Zebra Biologics and Scripps Research Institute disclose Trk-B agonist antibodies

Nov. 22, 2017

No Comments

Nightstar Therapeutics licenses gene therapy for Stargardt disease

Nov. 9, 2017

No Comments

Invirsa closes seed financing to develop INV-102

Nov. 9, 2017

No Comments

DSMB clears ReNeuron's retinitis pigmentosa trial to advance into phase II

Nov. 8, 2017

No Comments

Nicox announces FDA approval of Vyzulta, recaps pipeline progress

Nov. 3, 2017

No Comments

RegeneRx reports results from ARISE-2 study of RGN-259

Nov. 2, 2017

No Comments

Kala Pharmaceuticals submits NDA for Inveltys to FDA

Oct. 26, 2017

No Comments

Imprimis Pharmaceuticals launches subsidiary

Oct. 25, 2017

No Comments

Gemini Therapeutics completes series A financing

Oct. 18, 2017

No Comments

FDA advisory committee votes in favor of Rhopressa

Oct. 16, 2017

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Zebra Biologics and Scripps Research Institute disclose Trk-B agonist antibodies

Nightstar Therapeutics licenses gene therapy for Stargardt disease

Invirsa closes seed financing to develop INV-102

DSMB clears ReNeuron's retinitis pigmentosa trial to advance into phase II

Nicox announces FDA approval of Vyzulta, recaps pipeline progress

RegeneRx reports results from ARISE-2 study of RGN-259

Kala Pharmaceuticals submits NDA for Inveltys to FDA

Imprimis Pharmaceuticals launches subsidiary

Gemini Therapeutics completes series A financing

FDA advisory committee votes in favor of Rhopressa

Today's news in brief

Today's news in brief

Second insulin receptor offers new therapeutic avenues

Mechanism underlying so-called idiopathic autism inception unveiled

Drug duo to Repare lack in gyno cancers? Phase I shows promise

Ocular RSS

Ocular
RSS